Literature DB >> 16352376

The burden of Herpes Zoster: a prospective population based study.

Fiona T Scott1, Robert W Johnson, Mary Leedham-Green, Eleri Davies, W John Edmunds, Judith Breuer.   

Abstract

We analysed prospectively the medical, societal and economic burden among patients from 18 general practices in East London, serving 158,716 patients who presented to their general practitioners with acute Herpes Zoster over an 8-month period. One hundred and eighty-six patients with HZ were seen by GPs during the study period, of whom 96 were referred, 70 enrolled and 65 completed. PHN occurred in 13.4% of patients. The average overall cost of HZ in the first 6 months was calculated at pound524 per patient. Medical costs were highest in those aged over 65 and societal costs highest in those aged under 65 years.

Entities:  

Mesh:

Year:  2005        PMID: 16352376     DOI: 10.1016/j.vaccine.2005.09.026

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  64 in total

Review 1.  Herpes zoster.

Authors:  David W Wareham; Judith Breuer
Journal:  BMJ       Date:  2007-06-09

Review 2.  Tramadol for neuropathic pain in adults.

Authors:  Rudolf Martin Duehmke; Sheena Derry; Philip J Wiffen; Rae F Bell; Dominic Aldington; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2017-06-15

Review 3.  Methadone for neuropathic pain in adults.

Authors:  Ewan D McNicol; McKenzie C Ferguson; Roman Schumann
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

4.  Natural history of pain following herpes zoster.

Authors:  Hans Gustav Thyregod; Michael C Rowbotham; Michelle Peters; Jessica Possehn; Marlene Berro; Karin Lottrup Petersen
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

5.  Herpes zoster and postherpetic neuralgia in Catalonia (Spain).

Authors:  Luis Salleras; Montse Salleras; Patricia Salvador; Núria Soldevila; Andreu Prat; Patricio Garrido; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

Authors:  Lee Moore; Vanessa Remy; Monique Martin; Maud Beillat; Alistair McGuire
Journal:  Cost Eff Resour Alloc       Date:  2010-04-30

7.  Epidemiology of herpes zoster infection among patients treated in primary care centres in the Valencian community (Spain).

Authors:  Ana M Cebrián-Cuenca; Javier Díez-Domingo; María San-Martín Rodríguez; Joan Puig-Barberá; Jorge Navarro-Pérez
Journal:  BMC Fam Pract       Date:  2010-05-06       Impact factor: 2.497

8.  Impact of herpes zoster and post-herpetic neuralgia on patients' quality of life: a patient-reported outcomes survey.

Authors:  Thomas Weinke; Alexander Edte; Sonja Schmitt; Kati Lukas
Journal:  Z Gesundh Wiss       Date:  2010-03-21

9.  Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study.

Authors:  Leonardo Emberti Gialloreti; Monica Merito; Patrizio Pezzotti; Luigi Naldi; Antonio Gatti; Maud Beillat; Laurence Serradell; Rafaelle di Marzo; Antonio Volpi
Journal:  BMC Infect Dis       Date:  2010-08-03       Impact factor: 3.090

Review 10.  Postherpetic neuralgia in the elderly.

Authors:  R W Johnson; J McElhaney
Journal:  Int J Clin Pract       Date:  2009-09       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.